Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study

Gynecologic Oncology

Volumn 82, Issue 1, 2001, Pages 7-10

  Hurteau, Jean A ^a   Blessing, John A ^b   DeCesare, Steven L ^c   Creasman, William T ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiangiogenic; Ovarian cancer; Recombinant interleukin 12

Indexed keywords

PLATINUM DERIVATIVE; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG DISEASE; NEUROLOGIC DISEASE; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0034938171     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6255     Document Type: Article

References (22)

1. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
2. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
3. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
4. Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor
5. Molecular characterization of interleukin-12
6. IL- 12 receptor II. Distribution and regulation of receptor expression
7. IL-12 receptor I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts
8. Interleukin-12: Potential role in cancer therapy
9. Interleukin-12: A recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors
10. Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma production
11. Elevated levels of the soluble interleukin 2 receptor alpha are present in ovarian cancer patients: Evidence for activation of T-lymphocytes and possible use in management of ovarian cancer
12. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines
13. + T-cell subsets in vivo
14. Interleukin-12 mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system
15. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian anal other intra-abdominal cancers
16. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies
17. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
18. IL-10 inhibits human T-cell proliferation and IL-2 production
19. Interleukin 12: A new clinical player in cytokine therapy
20. Intraperitoneal administration of human recombinant interleukin-12 (rhIL-12) for the treatment of ovarian and GI cancer patients with progressive disease after standard chemotherapy
21. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
22. Inhibition of angiogenesis in vivo by interleukin 12